Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Pain. 2020 Oct;161(10):2344–2352. doi: 10.1097/j.pain.0000000000001921

Figure 1.

Figure 1.

IL-10 is critical for resolution of cisplatin-induced mechanical pain hypersensitivity. A. Mechanical sensitivity measured by von Frey hairs in WT and Il10−/− mice in response to cisplatin (2 mg/kg daily for 3 days) (n=4M+4F/group), repeated measure two-way ANOVA, interaction genotype x time F(11, 110) = 5.55, p<0.0001. B. mRNA levels of Il10 in spinal cord (SC) and sciatic nerve (SN) on day 8 after start of cisplatin treatment (n=5/groups), for SC unpaired t test, F (3, 4) = 6.98, p=0.044. C. Mechanical sensitivity measured by von Frey hairs in female and male Il10−/− mice in response to cisplatin (n=4/group). D. Effect of intrathecal administration of neutralizing anti-IL-10 antibody or control IgG (10 μg/mouse/day, on day 8, 9 and 10 after start of cisplatin treatment) on mechanical sensitivity after cisplatin or PBS administration in female and male mice (n= 4F+4M/group), repeated measure two-way ANOVA, interaction genotype x antibody F (39, 208) = 7.14, p<0.0001. The arrows represent the intrathecal injection. Data are shown as mean ± SEM.